Celldex Therapeutics (CLDX) to Post Earnings on Thursday

Celldex Therapeutics (NASDAQ:CLDX) is projected to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($1.06) per share and revenue of $0.7350 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:00 PM ET.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.80 million. On average, analysts expect Celldex Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Celldex Therapeutics Stock Performance

NASDAQ CLDX opened at $37.69 on Tuesday. Celldex Therapeutics has a twelve month low of $19.72 and a twelve month high of $40.30. The stock has a market capitalization of $2.96 billion, a PE ratio of -8.85 and a beta of 0.87. The stock has a 50-day simple moving average of $34.44 and a 200 day simple moving average of $31.15.

Analysts Set New Price Targets

CLDX has been the topic of several recent analyst reports. Wells Fargo & Company lifted their price target on Celldex Therapeutics from $48.00 to $72.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Wall Street Zen raised Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 12th. Morgan Stanley lowered their price objective on shares of Celldex Therapeutics from $44.00 to $40.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 22nd. UBS Group raised their price objective on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Finally, Guggenheim boosted their target price on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Celldex Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $54.62.

Hedge Funds Weigh In On Celldex Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. raised its holdings in Celldex Therapeutics by 14.3% in the 4th quarter. Invesco Ltd. now owns 90,144 shares of the biopharmaceutical company’s stock valued at $2,448,000 after acquiring an additional 11,258 shares in the last quarter. ADAR1 Capital Management LLC grew its holdings in shares of Celldex Therapeutics by 491.0% during the 4th quarter. ADAR1 Capital Management LLC now owns 646,767 shares of the biopharmaceutical company’s stock worth $17,566,000 after purchasing an additional 537,325 shares in the last quarter. XTX Topco Ltd grew its holdings in shares of Celldex Therapeutics by 552.7% during the 4th quarter. XTX Topco Ltd now owns 51,523 shares of the biopharmaceutical company’s stock worth $1,399,000 after purchasing an additional 43,629 shares in the last quarter. Virtus Investment Advisers LLC increased its position in shares of Celldex Therapeutics by 72.9% during the fourth quarter. Virtus Investment Advisers LLC now owns 9,671 shares of the biopharmaceutical company’s stock valued at $263,000 after purchasing an additional 4,079 shares during the period. Finally, Wellington Management Group LLP increased its position in shares of Celldex Therapeutics by 39.3% during the fourth quarter. Wellington Management Group LLP now owns 8,079,608 shares of the biopharmaceutical company’s stock valued at $219,442,000 after purchasing an additional 2,279,605 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.